Drugs that target advanced breast cancer could be beneficial for patients with a rare cancer that affects parts of the digestive system, a trial has found.
Tucatinib and trastuzumab work by blocking a protein known as human epidermal growth factor receptor 2 (HER2) in cancer cells to stop them from growing or spreading.
